Allarity Therapeutics Kicks Off Phase 3 Manufacturing for Lead Drug Stenoparib, Paving Way for Pivotal Trial
ALLR sits 69% above its 52-week low of $0.769.
Summary
Allarity Therapeutics announced it has initiated a Phase 3 manufacturing campaign for its lead drug candidate, stenoparib, with completion expected by Q3 2026. This critical operational step secures drug supply for anticipated pivotal-stage clinical development, particularly for advanced ovarian cancer, and all manufacturing payments have been completed. This news follows the recent Notice of Allowance for stenoparib's DRP® companion diagnostic on April 28, underscoring the company's focused efforts to advance this asset, which also holds FDA Fast Track designation. For a micro-cap biotech, this milestone significantly de-risks the path to late-stage trials and potential FDA approval, signaling strong confidence in stenoparib's therapeutic potential. Traders will now monitor for the commencement of the pivotal trial and further clinical data from the ongoing Phase 2 study.
At the time of this announcement, ALLR was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.8M. The 52-week trading range was $0.77 to $2.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.